$aTyr Pharma (LIFE.US)$ Following successful completion of P...

Following successful completion of PH2, aTyr plans to hold a meeting with FDA to discuss the PH3 study design as soon as possible, and data release is in the works. The company recently announced a collaboration with Ohio State University to develop a companion diagnosis as a predictive biomarker for granuloma formation to identify better responders to ATRY1923 in pulmonary sarcoidosis.